Incentivio is a developer of an intelligent guest engagement platform designed to enhance the restaurant experience in the digital age. The platform aims to help restaurants acquire new customers, increase visit frequency and spending, and foster customer loyalty. By leveraging technology, Incentivio enables restaurants to build meaningful relationships with their guests, ultimately driving digital revenue. Additionally, the platform helps reduce operational costs and generates incremental revenue, positioning restaurants to thrive in a competitive market.
Verve Motion specializes in the development of lightweight wearable exo-suits aimed at enhancing the safety and comfort of workers engaged in physically demanding tasks. By integrating robotics, apparel design, and movement science, the company creates innovative textile-based solutions that adapt to the movements of the wearer. These exo-suits provide support by delivering force at critical moments while remaining nonrestrictive, thereby promoting a safer work environment. Additionally, Verve Motion's designs contribute to a more restful experience for workers during their off-hours.
Ribon Therapeutics, Inc. is a biotechnology company based in Lexington, Massachusetts, founded in 2015. The company is focused on developing innovative cancer therapies that target monoPARP proteins, which are essential regulators of cancer cell survival. Ribon's scientific founders have made significant contributions to the understanding of PARPs, or poly(ADP-ribose) polymerases, and their roles in cancer. Leveraging this expertise, Ribon is establishing a proprietary drug discovery platform aimed at exploring the molecular actions and biological functions of monoPARPs. This platform supports the creation of a pipeline of therapeutics that selectively target these proteins to potentially treat cancer and other diseases. Ribon Therapeutics is supported by notable life science investors, enhancing its capability to advance its research and development efforts.
Pliant.io, Inc. is a Boston-based company founded in 2017 that specializes in infrastructure automation. The company provides an orchestration, automation, and response (OAR) platform known as Pliant, which enables IT operations teams to efficiently plan, build, and deploy API-level automations. This platform facilitates the automation of complex cross-domain processes through its graphical representations and uniform building blocks. Pliant's solutions cater to a variety of use cases, including virtual machine provisioning, server auditing and remediation, IT service management orchestration, hybrid network configuration, and application delivery and security. By enabling rapid development and deployment of IT automation, Pliant addresses the evolving demands of complex business processes.
Connected2Fiber helps the network industry transact and improve its return on marketing investment with the industry’s only SaaS marketplace enablement platform that combines Account Based Marketing, Location Intelligence with predictive algorithms that learns how to improve results. The platform helps network owners and network buyers improve transparency, speed and effectiveness with information, automation and predictive algorithms. Connected2Fiber is based in Hopkinton, MA, and was founded in 2015 by Ben Edmond. The Connected World was built to provide a better way to view, share, manage, learn and engage at a location level for networks.
Cyteir is developing the next generation of synthetic lethal therapies to treat cancer.Cyteir Therapeutics is creating breakthrough solutions to the major challenges facing cancer researchers today. Currently in development, is the answer to the oncology triumvirate: reducing side effects, reducing therapy resistance, inducing diseased cell self destruction.
Indico Data Solutions, Inc. is a Boston-based company that specializes in developing artificial intelligence solutions for automating the processing of unstructured content. Founded in 2013, Indico's platform allows enterprises to create customized machine learning models using smaller datasets, effectively enhancing the efficiency of labor-intensive document-based workflows. By focusing on automating tedious back-office tasks, Indico enables organizations to extract valuable insights from unstructured content, such as text and images. The company's innovative approach, known as transfer learning, empowers users to train machine learning models with significantly less data than traditional methods require. This capability helps businesses overcome common barriers to AI adoption, ultimately transforming their document processing into more profitable operations.
Q32 Bio is a biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases. Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief.
Q32 Bio consists of a team of scientists and industry veterans with strong expertise in immunology. The team has a strong track record of discovering and developing new and innovative therapies.
Nido Biosciences currently operates in healthcare services. Nido Biosciences specializes in the fields of biotechnology, healthcare, and personal health.
It is currently in stealth mode and was founded in 2018.
HelloTeam is an engagement and talent management platform focused on enhancing employee engagement and retention. The platform provides tools that enable organizations to develop data-driven people strategies supported by real-time insights and analytics. By fostering an environment where employees feel seen, heard, and valued, HelloTeam aims to create a more connected and inspired workforce.
Aerovate Therapeutics is a biotechnology company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Aerovate's program is a potentially disease-modifying drug, AV-101, for people who suffer from pulmonary arterial hypertension (PAH). AV-101 is a proprietary inhaled dry powder formulation of the drug imatinib that delivers this medicine directly to diseased lung tissues while reducing systemic adverse side effects.
The company was founded and incubated by RA Capital Management, a multi-stage investment manager focused on healthcare and life sciences.
Vor Biopharma, Inc. develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It offers VOR33, an eHSC product candidate that is in preclinical development to treat acute myeloid leukemia (AML). The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML cancer cells. Vor Biopharma, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.
Cyteir is developing the next generation of synthetic lethal therapies to treat cancer.Cyteir Therapeutics is creating breakthrough solutions to the major challenges facing cancer researchers today. Currently in development, is the answer to the oncology triumvirate: reducing side effects, reducing therapy resistance, inducing diseased cell self destruction.
Connected2Fiber helps the network industry transact and improve its return on marketing investment with the industry’s only SaaS marketplace enablement platform that combines Account Based Marketing, Location Intelligence with predictive algorithms that learns how to improve results. The platform helps network owners and network buyers improve transparency, speed and effectiveness with information, automation and predictive algorithms. Connected2Fiber is based in Hopkinton, MA, and was founded in 2015 by Ben Edmond. The Connected World was built to provide a better way to view, share, manage, learn and engage at a location level for networks.
Arrakis Therapeutics is a biopharmaceutical company focused on developing innovative drugs that target ribonucleic acid (RNA) to treat a variety of diseases, including cancer and rare genetic disorders. The company employs a unique drug discovery platform that integrates advanced RNA bioinformatics and structural tools, allowing it to identify new RNA targets and create RNA-targeted small molecules (rSMs). Its proprietary pipeline consists of these rSMs aimed at genetically validated targets across multiple disease areas. Additionally, Arrakis offers SHAPEware, a software tool that assists in predicting RNA secondary structures and potential ligand-binding sites. Founded in 2015 and based in Waltham, Massachusetts, Arrakis Therapeutics aims to enhance therapeutic options for patients through its cutting-edge research and development efforts.
Hyalex Orthopaedics, Inc. is a medical device company based in Lexington, Massachusetts, focused on developing innovative products that utilize HYALEX technology, a synthetic polymer engineered to mimic cartilage. Founded in 2016, the company specializes in creating a biomimetic material that can effectively simulate healthy cartilage to treat diseased or damaged joints. The unique properties of HYALEX allow it to maintain low friction and wear, even under the significant loads typically experienced in human joints. This capability enables surgeons to replace arthritic cartilage while preserving healthy bone. Although Hyalex Orthopaedics is advancing its product development, its offerings have not yet received approval for use in humans from any regulatory agency.
Vor Biopharma, Inc. develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It offers VOR33, an eHSC product candidate that is in preclinical development to treat acute myeloid leukemia (AML). The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML cancer cells. Vor Biopharma, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.
Ribon Therapeutics, Inc. is a biotechnology company based in Lexington, Massachusetts, founded in 2015. The company is focused on developing innovative cancer therapies that target monoPARP proteins, which are essential regulators of cancer cell survival. Ribon's scientific founders have made significant contributions to the understanding of PARPs, or poly(ADP-ribose) polymerases, and their roles in cancer. Leveraging this expertise, Ribon is establishing a proprietary drug discovery platform aimed at exploring the molecular actions and biological functions of monoPARPs. This platform supports the creation of a pipeline of therapeutics that selectively target these proteins to potentially treat cancer and other diseases. Ribon Therapeutics is supported by notable life science investors, enhancing its capability to advance its research and development efforts.
MC10, Inc. specializes in developing and selling wearable medical sensors that capture clinical-grade biometric and physiological data for use in clinical trials. Founded in 2008 and based in Lexington, Massachusetts, the company offers several innovative products, including BioStamp nPoint, which processes raw data into clinical metrics such as vital signs and sleep patterns; Kintinuum, a rehabilitation device for orthopedic surgery; WiSP, which provides cardiac monitoring and ECG recording; and BioStampMD, a flexible sensor designed to conform to the human body for comprehensive data collection. The BioStamp system enhances data acquisition by allowing for discreet and comfortable wear, thus facilitating targeted measurements of muscle activation and movement. MC10's dedication to creating flexible, conformal electronics aims to improve the quality of life by seamlessly integrating technology with human activity.
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases. The company's key product candidates include tebipenem pivoxil hydrobromide, an oral antibiotic aimed at treating MDR gram-negative infections in adults; SPR206, an intravenous agent targeting MDR gram-negative infections in hospital settings; and SPR720, an oral antibiotic for pulmonary non-tuberculous mycobacterial disease. Spero Therapeutics has entered various agreements, including a licensing partnership with Meiji Seika Pharma to develop tebipenem HBr and collaborations with Everest Medicines and the Bill & Melinda Gates Medical Research Institute for the development and commercialization of SPR206 and SPR720, respectively. Founded in 2013, Spero Therapeutics aims to address urgent medical needs through innovative therapeutic solutions for serious bacterial infections.
Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing precision genetic medicines for serious diseases. It utilizes its proprietary base editing technology, which allows for targeted modifications at the single base level in the genome without causing double-stranded breaks in DNA. Beam's therapeutic pipeline includes treatments for sickle cell disease, beta-thalassemia, pediatric T-cell acute lymphoblastic leukemia, pediatric acute myeloid leukemia, alpha-1 antitrypsin deficiency, glycogen storage disorder 1A, and various ocular and central nervous system disorders. The company aims to provide long-lasting cures through its innovative approaches, which include gene correction, gene modification, gene activation, gene silencing, and multiplex editing. Beam Therapeutics was founded in 2017 and is committed to advancing the field of genetic medicine through research and clinical collaborations, including a partnership with Magenta Therapeutics.
Cyteir is developing the next generation of synthetic lethal therapies to treat cancer.Cyteir Therapeutics is creating breakthrough solutions to the major challenges facing cancer researchers today. Currently in development, is the answer to the oncology triumvirate: reducing side effects, reducing therapy resistance, inducing diseased cell self destruction.
Indico Data Solutions, Inc. is a Boston-based company that specializes in developing artificial intelligence solutions for automating the processing of unstructured content. Founded in 2013, Indico's platform allows enterprises to create customized machine learning models using smaller datasets, effectively enhancing the efficiency of labor-intensive document-based workflows. By focusing on automating tedious back-office tasks, Indico enables organizations to extract valuable insights from unstructured content, such as text and images. The company's innovative approach, known as transfer learning, empowers users to train machine learning models with significantly less data than traditional methods require. This capability helps businesses overcome common barriers to AI adoption, ultimately transforming their document processing into more profitable operations.
Connected2Fiber helps the network industry transact and improve its return on marketing investment with the industry’s only SaaS marketplace enablement platform that combines Account Based Marketing, Location Intelligence with predictive algorithms that learns how to improve results. The platform helps network owners and network buyers improve transparency, speed and effectiveness with information, automation and predictive algorithms. Connected2Fiber is based in Hopkinton, MA, and was founded in 2015 by Ben Edmond. The Connected World was built to provide a better way to view, share, manage, learn and engage at a location level for networks.
Quantum Circuits, Inc., founded in 2015 and based in New Haven, Connecticut, specializes in the development, manufacturing, and sale of quantum computers utilizing superconducting devices. The company's primary objective is to create practical and useful quantum computers, while also commercializing components, devices, and software that support fundamental research and the scaling of quantum computing. Quantum Circuits focuses on the quantum circuit model, which facilitates universal and fault-tolerant operations through error correction. The technology employs superconducting Josephson junctions that function as solid-state quantum bits, or qubits. Founded by leading experts from Yale University's Department of Applied Physics, Quantum Circuits has made significant advancements in quantum devices and information processing, contributing to notable scientific achievements, including the development of a quantum bus for entangling qubits and the execution of quantum algorithms using solid-state devices.
Selecta Biosciences is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs aimed at treating and preventing human diseases. The company’s proprietary platform integrates advancements in immunobiology and nanotechnology to create targeted immunomodulatory nanoparticles. Its lead product, SEL-212, has completed Phase II clinical trials for chronic refractory gout. Additionally, Selecta is advancing gene therapy candidates, including SEL-302 and SEL-313, which are in preclinical development for rare metabolic disorders. The company has established collaborations and licensing agreements with various organizations, including Spark Therapeutics and the Massachusetts Institute of Technology. Founded in 2007 and headquartered in Watertown, Massachusetts, Selecta Biosciences continues to innovate in the biopharmaceutical field.
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing across a range of genetic disorders. The company’s various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 1/2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; and HMI-202 to treat metachromatic leukodystrophy. Homology Medicines, Inc. was founded in 2015 and is based in Bedford, Massachusetts.
Perceptive Automata, Inc. specializes in machine learning and computer vision technologies aimed at predicting human behavior to enhance the safety and efficacy of automated vehicles. Founded in 2014 and headquartered in Somerville, Massachusetts, the company addresses a critical challenge in automated driving: enabling vehicles to anticipate the actions of pedestrians, cyclists, and other drivers. This capability is vital for the smooth and safe operation of highly automated (L2/3) and fully autonomous (L4/5) vehicles, particularly in urban environments. By leveraging advanced AI that surpasses conventional physics-based models, Perceptive Automata facilitates a more natural driving experience and promotes the acceptance of autonomous vehicles in human-dominated road scenarios. The company collaborates with original equipment manufacturers, suppliers, and technology firms involved in the development of advanced driver-assistance systems and autonomous driving solutions, drawing on a team of experts from esteemed institutions such as Harvard, MIT, and Stanford.
Hyalex Orthopaedics, Inc. is a medical device company based in Lexington, Massachusetts, focused on developing innovative products that utilize HYALEX technology, a synthetic polymer engineered to mimic cartilage. Founded in 2016, the company specializes in creating a biomimetic material that can effectively simulate healthy cartilage to treat diseased or damaged joints. The unique properties of HYALEX allow it to maintain low friction and wear, even under the significant loads typically experienced in human joints. This capability enables surgeons to replace arthritic cartilage while preserving healthy bone. Although Hyalex Orthopaedics is advancing its product development, its offerings have not yet received approval for use in humans from any regulatory agency.
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases. The company's key product candidates include tebipenem pivoxil hydrobromide, an oral antibiotic aimed at treating MDR gram-negative infections in adults; SPR206, an intravenous agent targeting MDR gram-negative infections in hospital settings; and SPR720, an oral antibiotic for pulmonary non-tuberculous mycobacterial disease. Spero Therapeutics has entered various agreements, including a licensing partnership with Meiji Seika Pharma to develop tebipenem HBr and collaborations with Everest Medicines and the Bill & Melinda Gates Medical Research Institute for the development and commercialization of SPR206 and SPR720, respectively. Founded in 2013, Spero Therapeutics aims to address urgent medical needs through innovative therapeutic solutions for serious bacterial infections.
Arrakis Therapeutics is a biopharmaceutical company focused on developing innovative drugs that target ribonucleic acid (RNA) to treat a variety of diseases, including cancer and rare genetic disorders. The company employs a unique drug discovery platform that integrates advanced RNA bioinformatics and structural tools, allowing it to identify new RNA targets and create RNA-targeted small molecules (rSMs). Its proprietary pipeline consists of these rSMs aimed at genetically validated targets across multiple disease areas. Additionally, Arrakis offers SHAPEware, a software tool that assists in predicting RNA secondary structures and potential ligand-binding sites. Founded in 2015 and based in Waltham, Massachusetts, Arrakis Therapeutics aims to enhance therapeutic options for patients through its cutting-edge research and development efforts.
Biohaven is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline products include BHV3000-301, BHV3000-302, BHV3000-303, and others.
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases. The company's key product candidates include tebipenem pivoxil hydrobromide, an oral antibiotic aimed at treating MDR gram-negative infections in adults; SPR206, an intravenous agent targeting MDR gram-negative infections in hospital settings; and SPR720, an oral antibiotic for pulmonary non-tuberculous mycobacterial disease. Spero Therapeutics has entered various agreements, including a licensing partnership with Meiji Seika Pharma to develop tebipenem HBr and collaborations with Everest Medicines and the Bill & Melinda Gates Medical Research Institute for the development and commercialization of SPR206 and SPR720, respectively. Founded in 2013, Spero Therapeutics aims to address urgent medical needs through innovative therapeutic solutions for serious bacterial infections.
Ribon Therapeutics, Inc. is a biotechnology company based in Lexington, Massachusetts, founded in 2015. The company is focused on developing innovative cancer therapies that target monoPARP proteins, which are essential regulators of cancer cell survival. Ribon's scientific founders have made significant contributions to the understanding of PARPs, or poly(ADP-ribose) polymerases, and their roles in cancer. Leveraging this expertise, Ribon is establishing a proprietary drug discovery platform aimed at exploring the molecular actions and biological functions of monoPARPs. This platform supports the creation of a pipeline of therapeutics that selectively target these proteins to potentially treat cancer and other diseases. Ribon Therapeutics is supported by notable life science investors, enhancing its capability to advance its research and development efforts.
Ribon Therapeutics, Inc. is a biotechnology company based in Lexington, Massachusetts, founded in 2015. The company is focused on developing innovative cancer therapies that target monoPARP proteins, which are essential regulators of cancer cell survival. Ribon's scientific founders have made significant contributions to the understanding of PARPs, or poly(ADP-ribose) polymerases, and their roles in cancer. Leveraging this expertise, Ribon is establishing a proprietary drug discovery platform aimed at exploring the molecular actions and biological functions of monoPARPs. This platform supports the creation of a pipeline of therapeutics that selectively target these proteins to potentially treat cancer and other diseases. Ribon Therapeutics is supported by notable life science investors, enhancing its capability to advance its research and development efforts.
Provides infrastructure performance monitoring solutions for customers worldwide
Selecta Biosciences is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs aimed at treating and preventing human diseases. The company’s proprietary platform integrates advancements in immunobiology and nanotechnology to create targeted immunomodulatory nanoparticles. Its lead product, SEL-212, has completed Phase II clinical trials for chronic refractory gout. Additionally, Selecta is advancing gene therapy candidates, including SEL-302 and SEL-313, which are in preclinical development for rare metabolic disorders. The company has established collaborations and licensing agreements with various organizations, including Spark Therapeutics and the Massachusetts Institute of Technology. Founded in 2007 and headquartered in Watertown, Massachusetts, Selecta Biosciences continues to innovate in the biopharmaceutical field.
Voxel8 Inc. designs and manufactures electronic devices. It offers desktop 3D printers that are used to print thermoplastics or UV resins. The company also provides Project Wire, a cloud software tool that is used for designing 3D printable electronic devices that can be rapidly fabricated using the Voxel8 3D printer. Voxel8 Inc. was incorporated in 2013 and is based in Somerville, Massachusetts.
Kolltan Pharmaceuticals, Inc., is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories.
Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation — at atomic resolution — for the oncogenic activity of mutations that have been identified in a variety of human cancers.
Infinio addresses the most expensive bottleneck in virtual environments: storage performance.
Data center administrators buy more storage hardware when what they really want is better storage performance. Infinio offers a software-only solution instead.
Infinio has strong financial backing from tier-one venture capitalists including Highland Capital Partners, Bessemer Venture Partners, Lightspeed Venture Partners and Osage University Partners.
Sideris Pharmaceuticals Inc. is a privately held biopharmaceutical company that is focused on development of therapeutics for the treatment of transfusion-related iron overload. The company’s operations include facilities in Boston, MA, and in Gainesville, FL.
Evolv Technology specializes in noninvasive body scanners designed for touchless security screening, focusing on enhancing safety in public spaces. The company offers a range of products, including Evolv Express for firearm and bomb detection, Evolv Edge for checkpoint security, and Evolv Pinpoint for facial recognition. These systems are utilized in various settings, such as schools, stadiums, hospitals, and entertainment venues, to ensure the safety of employees, visitors, and VIPs. Founded in 2013 and headquartered in Waltham, Massachusetts, Evolv Technology aims to improve security protocols by integrating advanced sensors and artificial intelligence, enabling reliable scanning without compromising the visitor experience. The company has screened over 50 million individuals, successfully preventing more than 5,000 weapons from entering secure areas. With a leadership team comprising veterans from security agencies, Evolv is committed to providing effective solutions for both government and private sectors.
BA Insight develops integrated search technologies that help organizations enhance Microsoft SharePoint® usage
MC10, Inc. specializes in developing and selling wearable medical sensors that capture clinical-grade biometric and physiological data for use in clinical trials. Founded in 2008 and based in Lexington, Massachusetts, the company offers several innovative products, including BioStamp nPoint, which processes raw data into clinical metrics such as vital signs and sleep patterns; Kintinuum, a rehabilitation device for orthopedic surgery; WiSP, which provides cardiac monitoring and ECG recording; and BioStampMD, a flexible sensor designed to conform to the human body for comprehensive data collection. The BioStamp system enhances data acquisition by allowing for discreet and comfortable wear, thus facilitating targeted measurements of muscle activation and movement. MC10's dedication to creating flexible, conformal electronics aims to improve the quality of life by seamlessly integrating technology with human activity.
MC10, Inc. specializes in developing and selling wearable medical sensors that capture clinical-grade biometric and physiological data for use in clinical trials. Founded in 2008 and based in Lexington, Massachusetts, the company offers several innovative products, including BioStamp nPoint, which processes raw data into clinical metrics such as vital signs and sleep patterns; Kintinuum, a rehabilitation device for orthopedic surgery; WiSP, which provides cardiac monitoring and ECG recording; and BioStampMD, a flexible sensor designed to conform to the human body for comprehensive data collection. The BioStamp system enhances data acquisition by allowing for discreet and comfortable wear, thus facilitating targeted measurements of muscle activation and movement. MC10's dedication to creating flexible, conformal electronics aims to improve the quality of life by seamlessly integrating technology with human activity.
BA Insight develops integrated search technologies that help organizations enhance Microsoft SharePoint® usage
MC10, Inc. specializes in developing and selling wearable medical sensors that capture clinical-grade biometric and physiological data for use in clinical trials. Founded in 2008 and based in Lexington, Massachusetts, the company offers several innovative products, including BioStamp nPoint, which processes raw data into clinical metrics such as vital signs and sleep patterns; Kintinuum, a rehabilitation device for orthopedic surgery; WiSP, which provides cardiac monitoring and ECG recording; and BioStampMD, a flexible sensor designed to conform to the human body for comprehensive data collection. The BioStamp system enhances data acquisition by allowing for discreet and comfortable wear, thus facilitating targeted measurements of muscle activation and movement. MC10's dedication to creating flexible, conformal electronics aims to improve the quality of life by seamlessly integrating technology with human activity.
Virdante Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the development and commercialization of drugs for autoimmune and inflammatory diseases. Founded in 2007 and previously known as Centaurus Pharmaceuticals, the company specializes in creating antibody and Fc-fusion therapies aimed at addressing various autoimmune conditions. Through its innovative research and development efforts, Virdante Pharmaceuticals seeks to improve treatment options for patients suffering from these disorders.
Kolltan Pharmaceuticals, Inc., is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories.
Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation — at atomic resolution — for the oncogenic activity of mutations that have been identified in a variety of human cancers.
Provides infrastructure performance monitoring solutions for customers worldwide
At CampaignerCRM™, a j2® Global company, we're passionate about providing you with powerful CRM software that makes your sales process more efficient and gets you sales, revenue and customer results. We know that even the best sales people excel when they can focus on what they do best instead of being tied up generating forecasts, reports or entering data. That’s why we built CampaignerCRM. We put in all of the powerful features and functionality that make a sales team successful. Now your sales team can be free to focus on what it takes to make the sale. Your sales managers and executives automatically have accurate sales forecasting and the CRM reporting they need to stay up to speed on what’s going on in their sales pipeline. Most importantly, we made it all secure and easy-to-use with three solutions to help you manage your sales process.
Kolltan Pharmaceuticals, Inc., is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories.
Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation — at atomic resolution — for the oncogenic activity of mutations that have been identified in a variety of human cancers.
Provides infrastructure performance monitoring solutions for customers worldwide
At CampaignerCRM™, a j2® Global company, we're passionate about providing you with powerful CRM software that makes your sales process more efficient and gets you sales, revenue and customer results. We know that even the best sales people excel when they can focus on what they do best instead of being tied up generating forecasts, reports or entering data. That’s why we built CampaignerCRM. We put in all of the powerful features and functionality that make a sales team successful. Now your sales team can be free to focus on what it takes to make the sale. Your sales managers and executives automatically have accurate sales forecasting and the CRM reporting they need to stay up to speed on what’s going on in their sales pipeline. Most importantly, we made it all secure and easy-to-use with three solutions to help you manage your sales process.